238. ビタミンＤ抵抗性くる病/骨軟化症 Vitamin D-resistant rickets Clinical trials / Disease details

臨床試験数 : 29 / 薬物数 : 25 - (DrugBank : 11) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 20

diseases per page:

Showing 1 to 10 of 29 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04842032 (ClinicalTrials.gov)	October 5, 2021	30/3/2021	Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients Wit ...	An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, P ...	X-linked Hypophosphatemia (XLH)	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Recruiting	1 Year	12 Years	All	28	Phase 4	China
2	NCT04842019 (ClinicalTrials.gov)	August 30, 2021	30/3/2021	Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XL ...	An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, P ...	X-linked Hypophosphatemia (XLH)	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Recruiting	18 Years	65 Years	All	18	Phase 4	China
3	NCT04159675 (ClinicalTrials.gov)	October 1, 2020	7/11/2019	Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts	Effect of Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts From Patients Requiring Craniosynos ...	Craniosynostoses	Biological: osteoblast biology study	Hospices Civils de Lyon	NULL	Not yet recruiting	4 Months	18 Years	All	20		France
4	NCT04320316 (ClinicalTrials.gov)	July 31, 2020	11/3/2020	A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)	An Open Label Trial to Assess the Safety and Efficacy of KRN23, an Investigational Antibody to FGF23 ...	Epidermal Nevus Syndrome	Drug: Crysvita (burosumab-twza) Treatment	University of Alabama at Birmingham	Ultragenyx Pharmaceutical Inc	Completed	6 Months	N/A	Male	1	Phase 4	United States
5	NCT04045834 (ClinicalTrials.gov)	May 5, 2019	4/8/2019	Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induc ...	Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induc ...	PET / CT;PET / MR;Neuroendocrine Tumors;Osteomalacia	Device: 68Ga-DOTA-TATE PET/MR and PET/CT imaging	Wuhan Union Hospital, China	NULL	Recruiting	20 Years	80 Years	All	60		China
6	NCT03510455 (ClinicalTrials.gov)	February 27, 2019	26/4/2018	BGJ398 for the Treatment of Tumor-Induced Osteomalacia	BGJ398 for the Treatment of Tumor-Induced Osteomalacia	Tumor-Induced Osteomalacia;Oncogenic Osteomalacia	Drug: BGJ398	National Institute of Dental and Craniofacial Research (NIDCR)	NULL	Completed	18 Years	85 Years	All	4	Phase 2	United States
7	NCT03736564 (ClinicalTrials.gov)	January 31, 2019	30/10/2018	Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia	68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced ...	Osteomalacia	Combination Product: 68Ga-DOTATATE PET/CT	Mayo Clinic	NULL	Recruiting	18 Years	N/A	All	10	Phase 1/Phase 2	United States
8	NCT03581591 (ClinicalTrials.gov)	January 31, 2018	27/10/2017	Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypop ...	An Open Label Trial to Assess the Safety and Efficacy of Burosumab (KRN23), an Investigational Antib ...	Hypophosphatemia;Hypophosphatemic Rickets;Pain, Chronic	Biological: Burosumab	Redwood Dermatology Sciences	Ultragenyx Pharmaceutical Inc	Completed	N/A	18 Years	Female	1	Phase 3	United States
9	JPRN-JapicCTI-205284	09/1/2018	11/05/2020	A Study of KRN23 in Adult and Pediatric Patients with X-linked Hypophosphatemic Rickets/Osteomalacia ...	Phase 3 Long-term Extension Study of KRN23 in Patients with X-linked Hypophosphatemic Rickets/Osteom ...	Adult or pediatric XLH	Intervention name : burosumab INN of the intervention : KRN23 Dosage And administration of the interve ...	Kyowa Kirin Co., Ltd.	NULL	complete			BOTH	27	Phase 3	Japan, Asia except Japan
10	NCT04308096 (ClinicalTrials.gov)	January 9, 2018	26/2/2020	A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia ...	A Phase 3 Long-term Extension Study of KRN23 in Patients With X-linked Hypophosphatemic Rickets/Oste ...	XLH	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Active, not recruiting	N/A	N/A	All	27	Phase 3	Japan;Korea, Republic of

First Previous1 2 3Next Last